Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Atrium Therapeutics, Inc. Common Stock

Healthcare US RNA

12.26USD
0.09(0.74%)

Last update at 2026-06-04T20:00:00Z

Day Range

12.2612.58
LowHigh

52 Week Range

4.8330.84
LowHigh

Fundamentals

  • Previous Close 12.17
  • Market Cap2551.59M
  • Volume118028
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-252.83800M
  • Revenue TTM10.87M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM -141.18000M
  • Diluted EPS TTM-2.96

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -173.99500M -118.00900M -44.35500M -24.73400M -11.21600M
Minority interest - - - - -
Net income -169.07700M -117.37000M -43.98200M -32.12100M -11.93400M
Selling general administrative 37.73M 26.20M 13.46M 5.11M 2.44M
Selling and marketing expenses - - - - -
Gross profit 9.22M 9.33M 6.79M 2.32M 0.38M
Reconciled depreciation 1.39M 0.64M 0.37M 0.35M 0.38M
Ebit -180.30000M -118.69000M -44.65000M -17.33200M -10.49800M
Ebitda -178.91300M -118.05100M -44.27700M -16.98400M -10.11500M
Depreciation and amortization 1.39M 0.64M 0.37M 0.35M 0.38M
Non operating income net other - - - - -
Operating income -178.91300M -118.05100M -44.27700M -17.33200M -10.49800M
Other operating expenses 188.14M 127.38M 51.06M 19.65M 10.88M
Interest expense 5.69M 0.64M 0.21M 7.39M 0.72M
Tax provision - - - - -
Interest income 4.97M 0.10M 0.21M 0.00000M 0.00000M
Net interest income 4.97M 0.10M -0.00300M -7.38700M -0.71800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.91800M -0.63900M -0.37300M 7.39M 0.72M
Total revenue 9.22M 9.33M 6.79M 2.32M 0.38M
Total operating expenses 188.14M 127.38M 51.06M 19.65M 10.88M
Cost of revenue - - - - -
Total other income expense net 4.92M 0.04M -0.07800M -7.40200M -0.71800M
Discontinued operations - - - - -
Net income from continuing ops -173.99500M -118.00900M -44.35500M -24.73400M -11.21600M
Net income applicable to common shares -173.99500M -118.00900M -44.35500M -24.73400M -11.21600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 628.55M 638.80M 427.58M 333.90M 96.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 14.05M 12.21M 5.60M 3.54M 1.10M
Total liab 127.79M 60.73M 46.15M 27.68M 162.26M
Total stockholder equity 500.76M 578.08M 381.43M 306.22M -65.35700M
Deferred long term liab - - - - -
Other current liab 39.87M 39.12M 23.02M 10.90M 1.31M
Common stock 0.00800M 0.00700M 0.00500M 0.00400M 0.00100M
Capital stock 0.00800M 0.00700M 0.00500M 0.00400M 0.00000M
Retained earnings -570.76400M -358.54400M -184.54900M -66.54000M -22.18500M
Other liab - 1.24M 6.53M 12.15M 15.14M
Good will - - - - -
Other assets 0.00000M 0.85M 0.85M 0.30M 0.60M
Cash 185.08M 340.40M 405.54M 328.14M 94.58M
Cash and equivalents - - - - -
Total current liabilities 80.68M 51.91M 29.66M 14.59M 10.24M
Current deferred revenue 28.36M 5.04M 4.86M 3.69M 3.84M
Net debt -175.23000M -329.70900M -395.58300M -327.20300M -89.64100M
Short term debt 3.64M 3.10M 1.77M 2.77M 2.77M
Short long term debt - - - - 2.77M
Short long term debt total 9.85M 10.69M 9.96M 0.94M 4.94M
Other stockholder equity 1071.39M 939.31M 566.16M 38.87M -43.17200M
Property plant equipment - 15.01M 15.59M 1.92M 0.63M
Total current assets 611.31M 622.94M 411.14M 331.68M 95.68M
Long term investments - - - - -
Net tangible assets - 578.08M 381.43M 306.22M -65.35700M
Short term investments 410.27M 270.33M 85.09M 6.68M -
Net receivables 1.91M 2.10M 0.90M 1.20M 0.80M
Long term debt - - - - 1.77M
Inventory - - - - -
Accounts payable 8.81M 4.64M 14.09M 7.75M 2.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.12M -2.69800M -0.18700M -0.00500M -1.64300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00400M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.85M 0.85M 0.75M 0.60M
Deferred long term asset charges - - - - -
Non current assets total 17.25M 15.86M 16.44M 2.22M 1.23M
Capital lease obligations 9.85M 7.58M 11.73M 0.94M 0.39M
Long term debt total - - - - 1.77M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -189.95500M -78.77700M -6.69300M -0.23500M -0.04900M
Change to liabilities 13.20M 1.60M 2.65M 19.38M 0.54M
Total cashflows from investing activities -189.95500M -82.51700M -7.78500M -0.23500M -0.04900M
Net borrowings - - -4.68300M 16.65M 4.98M
Total cash from financing activities 346.17M 176.32M 272.04M 89.23M 5.14M
Change to operating activities -3.37900M 3.74M -0.31700M -0.01900M 0.13M
Net income -173.99500M -118.00900M -44.35500M -24.73400M -11.21600M
Change in cash 19.95M -1.01400M 227.13M 91.49M -4.56000M
Begin period cash flow 320.70M 321.71M 94.58M 3.09M 7.65M
End period cash flow 340.65M 320.70M 321.71M 94.58M 3.09M
Total cash from operating activities -136.26800M -94.81300M -37.11700M 2.49M -9.65500M
Issuance of capital stock 344.78M 185.94M 300.28M 72.69M 0.00000M
Depreciation 1.39M 0.64M 0.37M 0.35M 0.38M
Other cashflows from investing activities - - - - -
Dividends paid - 0.00000M 0.44M 0.11M 0.11M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 0.44M 72.69M 0.16M
Other cashflows from financing activities 1.39M -9.62300M -21.36000M 92.07M -0.04900M
Change to netincome 26.52M 17.22M 4.50M 7.45M 0.43M
Capital expenditures 2.82M 3.74M 1.09M 0.23M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 9.82M 5.34M 2.33M 19.12M 0.67M
Stock based compensation 27.14M 17.06M 4.31M 0.41M 0.06M
Other non cash items -0.61500M 0.16M 0.14M 7.35M 0.45M
Free cash flow -139.09100M -98.55300M -38.20900M 2.25M -9.70400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RNA
Atrium Therapeutics, Inc. Common Stock		 0.09 0.74% 12.26 - - 200.88 3.83 139.64 -5.7172
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Atrium Therapeutics, Inc. Common Stock

10578 Science Center Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder & Chairman 1969
Ms. Sarah Boyce Pres, CEO & Director 1972
Mr. Michael F. MacLean Chief Financial & Bus. Officer 1966
Dr. W. Michael Flanagan Ph.D. Chief Technical Officer 1962
Dr. Arthur A. Levin Ph.D. Chief Scientific Officer 1954
Prof. Mark E. Davis Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s NA
Dr. Frank McCormick Ph.D. Scientific Founder & Member of Scientific Advisory Board 1950
Ms. Kathleen Gallagher Sr. VP of Corp. Communications & Investor Relations NA
Dr. John W. Wallen III VP of Intellectual Property, Gen. Counsel & Sec. 1958
Ms. Teresa McCarthy Chief HR Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.